Last updated: February 13, 2026
Etravirine (brand name: Intelence) is an non-nucleoside reverse transcriptase inhibitor (NNRTI) used predominantly in combination therapies for treating HIV-1 infections. Approved by the U.S. Food and Drug Administration (FDA) in 2008, it has maintained a niche market due to its efficacy against drug-resistant HIV strains.
Market Size and Distribution
Global Market Valuation (2022-2027):
The global HIV antiviral drug market was valued at approximately $7.2 billion in 2022. Etravirine’s specific segment is estimated at $200 million to $300 million, representing roughly 4-4.2% of the broader market, driven by its role in salvage therapy for resistant HIV cases.
Projected Compound Annual Growth Rate (CAGR): 3.5-4.5% through 2027, inherently linked to HIV prevalence and resistance rates.
Market Share Factors:
- Compound therapy preferences favor drugs with established resistance profiles.
- Etravirine’s niche is heavily focused on patients with NNRTI-resistant HIV strains.
- Presence of cheaper generics (if approved elsewhere) could impact pricing and market share.
Geographic Distribution:
- United States: Largest market due to high HIV prevalence (~1.2 million people living with HIV, CDC 2021).
- Europe: Significant market share; varies by healthcare system and drug reimbursement policies.
- Emerging markets (Asia-Pacific, Africa): Lower penetration but growing due to increasing HIV cases.
Competitive Landscape
Major competitors include other NNRTIs (e.g., rilpivirine, doravirine) and integrase inhibitors (e.g., dolutegravir, bictegravir). Etravirine’s advantage is its activity against resistant strains but faces pricing pressure from patent expiration or generic alternatives elsewhere.
Key Industry Players (2022):
- Johnson & Johnson (full rights for Intelence in the US).
- GSK and other pharmaceutical developers focusing on resistance management.
Patent Status:
- Originally under patent until 2023-2025 in various markets.
- Patent cliffs could lead to generic competition, lowering prices.
Pricing Trends and Projections
Current Pricing:
- Retail list price (US): Approximately $2,000 - $3,000 per month for a standard regimen.
- Wholesale price: Approx. $1,800 - $2,500 per month (varies by distributor and insurance).
Factors Affecting Price Trends:
- Patent expiration anticipated between 2023-2025.
- Entry of generics could reduce prices by 50-70%.
- Reimbursement policies and negotiated discounts influence actual transaction prices.
| Projected Price Movements (2023-2027): |
Year |
Price Range (US$ per month) |
Notes |
| 2023 |
$1,500 - $2,500 |
Patent expiry effects begin, discounts intensify. |
| 2024 |
$1,000 - $2,000 |
Generic competition increases, prices decline. |
| 2025 |
$700 - $1,200 |
Market stabilizes; branded-only core remains. |
| 2026-2027 |
$600 - $1,000 |
Further price erosion but stabilization at lower levels. |
Comparison of Price Decline:
Patented drugs with high barriers can maintain premiums exceeding $2,000/month for a few years post-launch. Entry of generics typically accelerates price declines, often reaching 50-70% reduction within 2-3 years of patent expiry.
Regulatory and Policy Impact on Market and Price
- Pricing regulation: US Medicare/Medicaid negotiate drug prices, limiting profit margins.
- Patent challenges: Legal disputes or patent challenges may accelerate generic entry.
- Global Access Initiatives: Widespread HIV treatment programs in low-income countries prioritize affordability, often resulting in significantly discounted prices for Etravirine through negotiated international deals.
Future Outlook
- Market Growth Drivers: Increasing adoption of combination therapies tailored for resistant HIV strains; rising global HIV prevalence; improved access to treatment in emerging markets.
- Potential Challenges: Patent expiration leading to generic competition; similar efficacy NNRTIs with lower prices; shifts towards integrase-based regimens with longer durations and better tolerability.
Key Takeaways
- The Etravirine market accurately represents a niche for resistant HIV treatment, with total market size of roughly $200-300 million in 2022.
- Market growth remains steady with a CAGR of approximately 3.5-4.5% through 2027, driven by increasing HIV prevalence and resistance issues.
- Prices for Etravirine are expected to decline from around $2,000 per month in 2022 to approximately $600-$1,000 by 2027, primarily due to patent expiration and generic competition.
- Geographic and political factors significantly influence market dynamics and pricing, especially in emerging markets.
- The drug’s future remains tied to resistance management strategies and patent status.
FAQs
1. When is Etravirine expected to lose patent protection?
Patent protections in key territories are set to expire between 2023 and 2025, opening the market to generics.
2. How does Etravirine compare price-wise with alternative HIV treatments?
Etravirine's monthly cost remains higher than many first-line therapies, which often cost below US$1,000 per month once generics enter the market.
3. What factors could boost Etravirine's market share?
Increased prevalence of NNRTI-resistant HIV strains and clinician preference for its activity spectrum could bolster demand.
4. Are there significant regulatory hurdles facing Etravirine in emerging markets?
Yes. Pricing regulations, patent challenges, and funding mechanisms influence market penetration.
5. What is the outlook for Etravirine in treatment protocols?
Though niche remains for resistant cases, newer drugs with longer durations and fewer side effects may impact its positioning.
References
- CDC. HIV Surveillance Report, 2021.
- IQVIA. Global HIV Antivirals Market Data, 2022.
- FDA. Etravirine (Intelence) product label, 2008.
- MarketsandMarkets. HIV Drugs Market, 2022.
- EvaluatePharma. Price Trends and Patent Expiry Data, 2022.
